Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | September 19, 2026 | September 22, 2026 |
| Moelis & CoMC · Entity 3898 | Director | November 14, 2018 | November 16, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 08, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 19, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,802 |
Reported balance
After 2026-09-19 transaction · row 1
1 source rowRow 1 · 2026-09-19 · Grant · Acquired 107 · Balance 95,802 F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 407 |
Reported balance
Holding disclosure · report date 2026-09-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 407 F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026.
F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Moelis & Co
Report date November 14, 2018 · Filed November 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2017 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,156.96 |
Reported balance
After 2018-11-14 transaction · row 1
1 source rowRow 1 · 2018-11-14 · Grant · Acquired 13.39 · Balance 1,156.96 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 706.23 |
Reported balance
After 2018-11-14 transaction · row 2
1 source rowRow 2 · 2018-11-14 · Grant · Acquired 8.17 · Balance 706.23 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Elective Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,059.34 |
Reported balance
After 2018-11-14 transaction · row 3
1 source rowRow 3 · 2018-11-14 · Grant · Acquired 12.26 · Balance 1,059.34 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock.
F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs.
Pacira BioSciences, Inc.
Report date June 08, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,247 |
Reported balance
After 2022-06-08 transaction · row 1
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 1,160 · Balance 13,247 F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.39 · Expires 2032-06-08 | Direct | 8,225 |
Reported balance
After 2022-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-08 · Grant · Acquired 8,225 · Balance 8,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,739 F1 · kind: On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting achievement, on or before December 31, 2025, of non-GAAP operating income profitability for a 12-month calendar year, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 13, 2025. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 300 | $252.27 | $75,681.00 |
DisclosureSEC source: 0001735276-24-000108 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,880 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.09 to $252.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,933 | $251.42 | $737,414.86 |
DisclosureSEC source: 0001735276-24-000108 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,180 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07 to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,131 | $250.68 | $283,519.08 |
DisclosureSEC source: 0001735276-24-000108 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,113 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05 to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 762 | $249.60 | $190,195.20 |
DisclosureSEC source: 0001735276-24-000108 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,244 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00 to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 93 | $247.77 | $23,042.61 |
DisclosureSEC source: 0001735276-24-000108 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,006 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76 to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 22:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 10,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000108 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,099 F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024. Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 00:01 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000085 · edgardoc.xml · derivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,352 Underlying: Common Stock · 15,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024. F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 28, 2023. Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 00:01 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15,000 | $280.00 | $4,200,000.00 |
DisclosureSEC source: 0001735276-24-000085 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,441 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 00:01 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $85.00 | $1,275,000.00 |
DisclosureSEC source: 0001735276-24-000085 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| August 01, 2024 Filed Aug 3, 2024 00:01 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,148 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000077 · edgardoc.xml · derivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,352 Underlying: Common Stock · 15,148 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024. F3 · derivative.exercise_date: The stock option was fully vested as of 02/28/2023. Read SEC document |
| August 01, 2024 Filed Aug 3, 2024 00:01 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15,148 | $270.00 | $4,089,960.00 |
DisclosureSEC source: 0001735276-24-000077 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,441 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| August 01, 2024 Filed Aug 3, 2024 00:01 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,148 | $85.00 | $1,287,580.00 |
DisclosureSEC source: 0001735276-24-000077 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| July 11, 2024 Filed Jul 13, 2024 00:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,093 | $261.00 | $1,851,273.00 |
DisclosureSEC source: 0001735276-24-000075 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,441 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 863 | $235.19 | $202,968.97 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 13 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,534 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 957 | $234.66 | $224,569.62 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 12 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,397 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 595 | $233.53 | $138,950.35 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,354 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,119 | $232.54 | $260,212.26 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,949 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 511 | $231.59 | $118,342.49 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,068 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,572 | $229.93 | $361,449.96 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,579 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,374 | $229.06 | $314,728.44 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,151 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 666 | $228.30 | $152,047.80 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,525 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 177 | $226.82 | $40,147.14 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,191 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 93 | $225.55 | $20,976.15 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,368 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $224.99 to $225.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 66 | $224.17 | $14,795.22 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,461 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.92 to $224.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 308 | $221.71 | $68,286.68 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,527 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $221.37 to $222.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 16,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000068 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,835 F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on June 24, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 46,394 | $0.00 Strike: $152.61 | $0.00 |
DisclosureSEC source: 0001735276-24-000027 · edgardoc.xml · derivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,394 Underlying: Common Stock · 46,394 shares Expires 2034-03-01 F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vesting in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 23,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000027 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,882 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. F2 · balance_after: The Reporting Person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 23,754 newly awarded RSUs and 48,128 shares of common stock. The Reporting Person also holds 11,842 unvested RSUs that were previously reported in Table II. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8 | $158.09 | $1,264.72 |
DisclosureSEC source: 0001735276-24-000018 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,128 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 84 | $157.30 | $13,213.20 |
DisclosureSEC source: 0001735276-24-000018 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,136 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 588 | $156.38 | $91,951.44 |
DisclosureSEC source: 0001735276-24-000018 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,220 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 993 | $155.45 | $154,361.85 |
DisclosureSEC source: 0001735276-24-000018 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,808 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,259 | $154.54 | $194,565.86 |
DisclosureSEC source: 0001735276-24-000018 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,801 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 5,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000018 · edgardoc.xml · derivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,842 Underlying: Common Stock · 5,921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F8 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 17,763 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. F8 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 17,763 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000018 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 840 | $149.03 | $125,185.20 |
DisclosureSEC source: 0001735276-24-000007 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,139 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.96 to $149.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,614 | $148.24 | $535,739.36 |
DisclosureSEC source: 0001735276-24-000007 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,979 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.88 to $148.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,576 | $147.50 | $379,960.00 |
DisclosureSEC source: 0001735276-24-000007 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,593 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $146.88 to $147.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 16,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000007 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,169 F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting $1.5 billion in total annual revenue, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 15, 2024. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 192 | $189.31 | $36,347.52 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,216 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 17 | $188.40 | $3,202.80 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,408 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 101 | $187.37 | $18,924.37 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,425 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,107 | $186.39 | $206,333.73 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,526 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,869 | $185.54 | $346,774.26 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,633 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 771 | $184.70 | $142,403.70 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,502 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,273 F2 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 22:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 5,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000077 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,414 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 533 | $197.08 | $105,043.64 |
DisclosureSEC source: 0001735276-23-000048 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,332 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 331 | $195.65 | $64,760.15 |
DisclosureSEC source: 0001735276-23-000048 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,865 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.